Clinical Trial Detail

NCT ID NCT02502708
Title Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors NewLink Genetics Corporation
Indications

malignant glioma

malignant ependymoma

brain cancer

medulloblastoma

Therapies

Indoximod

Temozolomide

Age Groups: child adult

No variant requirements are available.